A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
![COVID-19 tracker: Regeneron's antibody cocktail hit by safety concerns; Novo's Rybelsus emerging from pandemic slump | FiercePharma COVID-19 tracker: Regeneron's antibody cocktail hit by safety concerns; Novo's Rybelsus emerging from pandemic slump | FiercePharma](https://qtxasset.com/fiercepharma/1597166780/coronavirus.jpg?BmcQIKzuQ5aqGswWWQ2D4IklxjT_mLZE)
COVID-19 tracker: Regeneron's antibody cocktail hit by safety concerns; Novo's Rybelsus emerging from pandemic slump | FiercePharma
![Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology](https://www.frontiersin.org/files/Articles/520377/fimmu-11-00592-HTML-r1/image_m/fimmu-11-00592-g001.jpg)
Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology
![Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places](https://www.researchgate.net/profile/Norbert_Pardi/publication/340313439/figure/fig1/AS:875943132413958@1585852525943/figure-fig1_Q320.jpg)
Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places
![Nanomaterials | Free Full-Text | Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives | HTML Nanomaterials | Free Full-Text | Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives | HTML](https://www.mdpi.com/nanomaterials/nanomaterials-10-00364/article_deploy/html/images/nanomaterials-10-00364-g002.png)
Nanomaterials | Free Full-Text | Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives | HTML
![Moderna's coronavirus vaccine trial is fully enrolled, 37 percent of participants are minorities - The Washington Post Moderna's coronavirus vaccine trial is fully enrolled, 37 percent of participants are minorities - The Washington Post](https://arc-anglerfish-washpost-prod-washpost.s3.amazonaws.com/public/722KMCAHLEI6XBYZBXYVTUKHSQ.jpg)